Maestas Nicholas 4

What Happened

• Nicholas Maestas, Chief Financial Officer of Rani Therapeutics Holdings, Inc. (RANI), was granted a derivative award for 2,000,000 shares on July 17, 2026. The Form 4 reports an acquisition at $0.00 (no cash paid at grant). This is an award/grant (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-07-17; Form 4 filed: 2026-07-21 (filed on time).
• Reported acquisition: 2,000,000 shares; reported price: $0.00; reported value: $0.
• Shares owned after transaction: not specified in the provided details.
• Footnote (vesting): 25% of the shares vest on June 29, 2027; the remainder vests monthly at 1/48th per month thereafter over the next three years, contingent on continuous service per the company’s 2026 Inducement Plan.
• Transaction type: A = Award/Grant (derivative). No immediate sale or exercise was reported.

Context

• This appears to be a time‑based equity award (options or RSUs) that vests over four years. No cash exchanged at grant; the award represents future economic rights subject to vesting and company plan terms.
• Such grants are common executive compensation and do not by themselves indicate an immediate buying or selling signal. Future Form 4 filings will show vesting, exercises, or sales that change beneficial ownership.